The US Patent and Trademark Office (USPTO) granted Neptune Technologies and Bioressources, a new patent covering omega-3 phospholipids comprising polyunsaturated fatty acids, one of the main bioactive ingredients in all recognised krill oils.
However, Dr Ariel Katz, Enzymotec’s CEO, said: “Based on a thorough assessment of the patent by Enzymotec’s professional experts and third party consultants, we have concluded that there is no basis for the patent claims being asserted against Enzymotec and certain of its customers.
“I am convinced that these patent’s claims are invalid, unenforceable and not infringed based on prior art and severe faults in the process conducted by Neptune at the US Patent Office. A related European patent submitted by Neptune was revoked following an opposition process initiated by Enzymotec and we are confident that this patent will end in the same way.
“Neptune’s recent provocative actions and press release are without merit and Enzymotec will explore all available legal actions to protect itself and its customers including making claims against Neptune for any damages caused by this frivolous legal harassment.”?
Source: Enzymotec
© FoodBev Media Ltd 2024